

Nucleome Therapeutics

Succession plan for CSO

Oxford, UK, 5 August 2025 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company harnessing the power of non-coding human genetics to discover first-in-class antibody treatments for inflammatory diseases, today announces that Dr. Stephen Harrison will step down from the Company as of 31 October 2025. A search has commenced to appoint a CSO as we enter Nucleome’s next phase of growth into preclinical and clinical drug development.

Steve joined as CSO in 2023 at a critical point in Nucleome’s growth. His scientific leadership progressed the Company from its technology origins in high precision 3D genomics to the application of human genetics to reveal the molecular basis of inflammatory diseases. As result, we now have an emerging pipeline of potential antibody therapies based on unique insights into inflammatory disease mechanisms from the genetics of patients.

Dr. Mark Bodmer, CEO of Nucleome, said: “Steve’s passion is for working with early-stage companies and academic scientists to turn their insights into valuable biotech. As we move into the preclinical phase of development, Steve and Nucleome have decided that the time is right for a transition in research leadership in the Company. Steve would like to continue to follow opportunities to bring early science through to tangible value and we are now seeking a CSO to lead product development as we progress to the clinic. Steve will continue to work with the leadership team and Board to ensure a smooth transition. We give our deepest thanks to Steve for steering the Company’s science to its current position of strength and wish Steve the very best for his next scientific adventure.”

Contact information

Optimum Strategic Communications

Mary Clark, Vici Rabbetts, Joshua Evans

nucleome@optimumcomms.com

+44 (0) 20 8078 4357

Notes to Editors

About Nucleome Therapeutics

Nucleome is using breakthrough genomics technologies to discover first-in-class antibody therapeutics for inflammatory diseases. The approach is based solely on human disease genetics and biology. Nucleome is able, for the first time, to reveal molecular mechanisms of disease and select drug targets using human genetic variants in the non-coding genome that alter gene expression. The Company’s proprietary 3D genomics combines lab and machine learning technologies which can be applied to any set of disease-associated variants.

Lead program NTP464 is an antibody that activates an inflammation checkpoint. NTP464 stimulates natural cellular processes of inflammation resolution, a new principle in the treatment of inflammation with huge potential patient benefit. Other multiple targets based on the genetics of inflammatory diseases are in discovery.

Nucleome is backed by a world-class syndicate of investors that includes M Ventures, the strategic corporate venture capital arm of Merck KGaA; Johnson and Johnson Innovation-JJDC, Inc. (“JJDC”), the strategic venture capital arm of Johnson & Johnson; Pfizer Ventures, the venture group of Pfizer; British Business Bank; and founding investor Oxford Science Enterprises.

Visit our website to find out more at: www.nucleome.com